The very large phase 1b was successful in reducing both the positive and negative symptoms of schizophrenia (PANSS and subunits), which likely played a large role in ABBV paying 8.7B for the company. Would be interesting to see if there were significant differences in inclusion/exclusion criteria between studies. Schizophrenia studies can usually be just 5-6 weeks long so a large Phase 1b should have been more predictive.
The SP was trimmed 25B which seems to be a little punitive for an 8B poor deal (still has some value left: the GABA modulator in phase 2 for focal epilepsy and for panic disorder seems like an interesting MOA; also a PD drug I haven't looked at yet)
Market Data 
Markets 
AI
